EI
CRNX icon

EAM Investors’s Crinetics Pharmaceuticals CRNX Stock Holding History

EAM Investors’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-57,216
Closed -$2.92M – 281
2024
Q3 		$2.92M Buy
57,216
+37
+0.1% +$1.91K 0.44% 124
2024
Q2 		$2.56M Sell
57,179
-49,435
-46% -$2.28M 0.42% 124
2024
Q1 		$4.99M Buy
106,614
+1,609
+2% +$63K 0.78% 13
2023
Q4 		$3.74M Buy
105,005
+10,816
+11% +$332K 0.66% 52
2023
Q3 		$2.8M Buy
+94,189
New +$1.94M 0.54% 42
2022
Q1 		– Sell
-66,948
Closed -$1.9M – 303
2021
Q4 		$1.9M Buy
+66,948
New +$1.65M 0.31% 139

Other funds holding CRNX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

EAM Investors's CRNX Position: Q4 2024 in Review

EAM Investors sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2024, closing a stake of 57,216 shares — an estimated $2.92M sold.

EAM Investors first reported a position in CRNX in Q4 2021 and held it in 6 quarters. The position peaked at $4.99M in Q1 2024. 247 funds tracked by Wall St. Rank hold CRNX as of Q4 2024.

  • EAM Investors reported no remaining Crinetics Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • EAM Investors sold 57,216 Crinetics Pharmaceuticals shares in Q4 2024, an estimated $2.92M.
  • EAM Investors first reported a position in Crinetics Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • EAM Investors's Crinetics Pharmaceuticals position peaked at $4.99M in Q1 2024.
  • 247 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2024.

Based on EAM Investors's 13F filing for Q4 2024, filed 13 Feb 2025.